SCHEMBL6800933

SCHEMBL6800933

Cc1ccc(S(=O)(=O)OCCc2csc(NC(=O)OC(C)(C)C)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 1/20 0.44
MAPK14 Q16539 4/20 0.43
DDR2 Q16832 2/20 0.42
MAPK13 O15264 1/20 0.42
MAPK12 P53778 1/20 0.42
DDR1 Q08345 1/20 0.42
MAPK11 Q15759 1/20 0.42
CCR2 P41597 2/20 0.40
PI4KB Q9UBF8 1/20 0.40
ALDH1A1 P00352 4/20 0.39
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
PTPRB P23467 1/20 0.39
TSHR P16473 2/20 0.39
MAPK1 P28482 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HPGD P15428 1/20 0.39
LMNA P02545 1/20 0.38
CLK1 P49759 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7083749 0.87 MAPK14 (0.40) MAPK14DDR2MAPK13MAPK12DDR1
SCHEMBL2656976 0.85 SIRT1 (0.44) SIRT1CCR2PI4KBALDH1A1KMT2A
SCHEMBL6489184 0.81 KDM4E (0.40) CCR2ALDH1A1TSHRSMN1; SMN2
SCHEMBL6794653 0.80 PSMD10 (0.35) MAPK14ALDH1A1MEN1MAPTKMT2A
SCHEMBL27729888 0.78 SIRT1 (0.46) SIRT1CCR2PI4KBALDH1A1KMT2A
SCHEMBL26079065 0.78 RORC (0.42) ALDH1A1MEN1KMT2ATSHRSMN1; SMN2
SCHEMBL3103834 0.77 STAT3 (0.48) MAPK14ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL944485 0.77 PI4KB (0.51) SIRT1CCR2PI4KBALDH1A1KMT2A
SCHEMBL12742401 0.77 PTPRB (0.49) SIRT1PI4KBALDH1A1KMT2APTPRB
SCHEMBL6800670 0.77 KMT2A (0.56) ALDH1A1MEN1MAPTKMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed
EP-1326835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-16 EP disclosed
WO-2002028835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 SIRT1 1218/4885MAPK14 1991/4885DDR2 3721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.